<DOC>
	<DOCNO>NCT01212055</DOCNO>
	<brief_summary>Background : - Gene therapy investigate possible treatment individual immunodeficiency disease condition make difficult fight infection . Gene therapy avoids problem donor identification possible rejection bone marrow transplant use patient modify blood cell help treat disease . Researchers interested collect stem cell blood individual immunodeficiency disease order use cell develop potential gene therapy treatment . Objectives : - To collect blood stem cell patient immunodeficiency diseases tto test ability correct defect cell test tube . . Eligibility : - Individuals 18 40 year age immunodeficiency disease . - Individuals human immunodeficiency virus ( HIV ) able participate study . Design : - Participants provide initial blood sample disease screening ( hepatitis B C , syphilis , virus like Epstein-Barr virus , herpes simplex virus , toxoplasmosis ) check kidney liver function . - Starting 5 day blood donation , participant receive daily injection drug call G-CSF ( granulocyte colony stimulate factor , filgrastim ) , push stem cell bone marrow bloodstream . Participants receive injection National Institutes Health Clinical Center . - On day 5 , participant single leukapheresis procedure collect stem cell blood . - No additional treatment provide part protocol . The cell collect use fore experiment lab use treat individual disease .</brief_summary>
	<brief_title>Apheresis Patients With Immunodeficiency</brief_title>
	<detailed_description>BACKGROUND : Primary immunodeficiency disease ( PID ) represent candidate genetic disorder new therapeutic approach . Our laboratory develop gene therapy patient PID use autologous CD34+ hematopoietic stem cell ( HSC ) . Gene therapy may circumvent problem allogeneic HSC transplantation , especially graft rejection graft-versus-host-disease . We particularly interest three PID : Dedicator CytoKinesis-8 ( DOCK8 ) deficiency , Leukocyte Adhesion Deficiency type 1 ( LAD-1 ) , GATA2 Deficiency . For DOCK8 deficiency , LAD-1 , disease gene clone . The genetic basis MonoMAC determine due mutation GATA2.. Testing new vector construct transduction condition gene therapy would considerably enhance acquisition peripheral blood CD34+ cell patient immunodeficiency disease . OBJECTIVES : To provide source granulocyte colony stimulate factor ( G-CSF ) mobilize peripheral blood CD34+ hematopoietic stem cell ( HSC ) laboratory research study include optimization vector transduction condition gene therapy DOCK8 deficiency , LAD-1 , MonoMAC . ELIGIBILITY : Patients 15-40 year old DOCK8 deficiency , LAD-1 , MonoMAC meet eligibility requirement consider protocol . DESIGN : Patients 15-40 year old DOCK8 deficiency , LAD-1 , MonoMAC receive five day G-CSF follow single apheresis . CD34+ cell select frozen aliquot Cell Processing Section Department Transfusion Medicine . No treatment , investigational therapy administer protocol .</detailed_description>
	<criteria>INCLUSION CRITERIA : 1 . Patient age 1540 year . 2 . Diagnosis DOCK8 deficiency , LAD1 , MonoMAC : DOCK8 Deficiency Homozygous compound heterozygous mutation DOCK8 gene . LAD1 Less 10 % CD18 expression neutrophil surface . GATA2 Deficiency 1 . Onset immunodeficiency disease beyond infancy . 2 . Clinical history least two episode lifethreatening infection opportunistic organism . 3 . Mutation GATA2 Gene c ) Serum creatinine &lt; 1.5 mg/dL . ) Total Bilirubin &lt; 3mg/dl , ALT AST &lt; 5 time upper limit normal . e ) Ability give inform consent . f ) Adequate venous access peripheral apheresis , consent use temporary central venous catheter apheresis . g ) Female patient childbearing age must negative urine pregnancy test within one week begin GCSF administration . h ) A patient lactating must willing able interrupt breastfeed substitute formula feed infant period filgrastim administration two day follow final dose . Filgrastim may secrete human milk , although bioavailability source know . Limited clinical data suggest shortterm administration filgrastim sargramostim neonate associate adverse outcome j ) Potential patient must screen apheresis nurse check venous access protocol entry . Antecubital vein must adequate peripheral access leukapheresis , patient must give write consent placement temporary central venous access catheter . EXCLUSION CRITERIA : 1 . HIV infection . 2 . Chronic hepatitis B hepatitis C virus infection . 3 . History psychiatric disorder may compromise compliance protocol , allow appropriate inform consent . 4 . Active infection respond antimicrobial therapy . f ) Pregnant . The effect breastmilk also unknown may harmful infant ; therefore , woman breast feed interval study entry collection . g ) Sexually active individual capable become pregnant unable unwilling use effective form ( ) contraception time enrol study . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . Males protocol must use effective form contraception study entry . h ) Presence active malignancy another organ system hematopoietic system . ) History hypertension control medication , stroke , severe heart disease . Individuals symptomatic angina consider severe heart disease eligible . j ) Other medical contraindication stem cell donation ( i.e . severe atherosclerosis , autoimmune disease , iritis episcleritis , deep venous thrombosis , cerebrovascular accident ) k ) Thrombocytopenia ( platelet le 50,000 per microL ) baseline evaluation . l ) Patients receive experimental therapy investigational agent . ) Sensitivity filgrastim E. coliderived recombinant protein product . n ) Patients must test negative transfusiontransmissible infectious agent , include hepatitis B ( HBsAg ) , hepatitis C ( antiHCV ) , HIV ( antiHIV1/2 ) .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 18, 2016</verification_date>
	<keyword>PBSC Collection</keyword>
	<keyword>Immunodeficiency</keyword>
	<keyword>Spectra Apheresis System</keyword>
	<keyword>Stem Cell Mobilization</keyword>
	<keyword>Leukapheresis</keyword>
</DOC>